Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC

Medema R.H.CHIA-CHI LINCHIH-HSIN YANG2020-05-262020-05-2620111078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-80054109912&doi=10.1158%2f1078-0432.CCR-11-0541&partnerID=40&md5=58cff2011bdd0eb8203ec7ef380bd922https://scholars.lib.ntu.edu.tw/handle/123456789/495073Cytotoxic platinum-doublet chemotherapy that includes antimitotic agents is a current standard of care in advanced non-small cell lung cancer (NSCLC). Microtubule-targeting antimitotics, taxanes, and Vinca alkaloids are effective anticancer therapeutics that affect both dividing and nondividing cells. A new generation of antimitotic agents that target regulatory proteins-mitotic kinases and kinesins-has the potential to overcome the limitations related to the role of tubulin in nondividing cells that are associated with traditional antimitotics. This review concentrates on Polo-like kinase 1, a key regulator of mitosis, outlines a rationale for its development as an anticancer target, and discusses data from preclinical and clinical studies of Plk1 inhibitors with a particular focus on NSCLC. ?2011 AACR.[SDGs]SDG34 (8 cyclopentyl 7 ethyl 5,6,7,8 tetrahydro 5 methyl 6 oxo 2 pteridinylamino) 3 methoxy n (1 methyl 4 piperidinyl)benzamide; cytotoxic agent; gsk 461364; hmn 176; hmn 214; on 01910 na; on 01919 na; pemetrexed; platinum; polo like kinase 1 inhibitor; polo like kinase inhibitor; unclassified drug; volasertib; abdominal pain; anemia; anorexia; blood toxicity; bone pain; cancer chemotherapy; cancer combination chemotherapy; cancer pain; colorectal cancer; defecation; drug dose escalation; drug eruption; drug targeting; electrolyte disturbance; fatigue; febrile neutropenia; flatulence; hematologic malignancy; human; hyperglycemia; leukopenia; lung embolism; lung non small cell cancer; lymphocytopenia; metastasis; mitosis inhibition; monotherapy; multiple cycle treatment; myalgia; nausea; nausea and vomiting; neuropathy; neutropenia; ovary carcinoma; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phlebitis; priority journal; pruritus; recommended drug dose; review; RNA interference; sepsis; side effect; single drug dose; solid tumor; stomatitis; thrombocytopenia; urge ot defecate; urge to defecate; venous thromboembolism; Antimitotic Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Protein-Serine-Threonine Kinases; Proto-Oncogene ProteinsPolo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLCReview10.1158/1078-0432.CCR-11-0541220030732-s2.0-80054109912